natgillin/translations-raw huggingface dataset:
Reversering af neutropeni
For reversal of neutropenia
reversi- belt encefalo-
reversible encephalo
reversibel
dysgeusia
reversibel
System Organ Class
reversibel mandlig infertilitet.
Reversible male infertility.
Reversibel neutropeni, trombocytopeni eller anæmi udvikledes hos enkelte hunde, som blev behandlet med 8 eller 10 mg/kg/dag (total olanzapin dosis (AUC) var 12-15 gange højere end human dosis p å 12 mg).
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reversibel neutropeni, trombocytopeni eller anæmi udvikledes hos enkelte hunde, som blev behandlet med 8 eller 10 mg/kg/dag (total olanzapin dosis (AUC) var 12-15 gange højere end human dosis p å 12 mg).
Reversible neutropenia, thrombocytopenia, or anaemiaa developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reversibel neutropeni, trombocytopeni eller anæmi udvikledes hos enkelte hunde, som blev behandlet med 8 eller 10 mg/kg/dag (total olanzapin dosis (AUC) var 12-15 gange højere end human dosis p å 12 mg).
Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reversibel neutropeni, trombocytopeni eller anæmi udvikledes hos enkelte hunde, som blev behandlet med 8 eller 10 mg/kg/dag (total olanzapin dosis arealet under kurven var 12-15 gange højere end human dosis på 12 mg).
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reversibel rødfarvning af hud og slimhinder (se ovenfor).
Reversible red colouration of the skin and mucous membranes (see above).
reversibel trombocyto- peni4
infusion-related acute reversible thrombocytopenia
Reversibel, selektiv MAO-A-hæmmer (moclobemid)
Reversible, selective MAO-A inhibitor (moclobemide)
Reversibelt posterior leukoencefalopati-syndrom (RPLS), et syndrom der er kendetegnet ved hovedpine, forvirring, kramper og synstab, som fortager sig efter nogen tid
Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome characterized by headache, confusion, seizures and visual loss which resolves after some time.
Reversibelt posteriort leukoencefalopatisyndrom
Reversible posterior leukoencephalopathy syndrome
Reversibelt posteriort leukoencefalopatisyndrom (RPLS) kan opstå i sjældne tilfælde i løbet af behandlingen med alle asparaginaser.
Reversible posterior leukoencephalopathy syndrome (RPLS) may occur rarely during treatment with any asparaginase.
reversibelt, posteriort leukoencefalopatisyndrom (en tilstand karakteriseret ved hovedpine, forvirring, krampeanfald og synstab)
Reversible posterior leukoencephalopathy syndrome (a condition characterised by headache, confusion, seizures and visual loss)
Reversibilitet af de toksikologiske ændringer blev observeret ved slutningen af en 4- ugers rekonvalescensperiode hos alle de undersøgte dyrearter.
Reversibility of the toxicologic changes was observed at the end of a 4-week recovery period in all animal species investigated.
Reversibiliteten af svær kongestiv hjerteinsufficiens (defineret som en sekvens på mindst to på hinanden følgende LVEF- værdier ≥50 % efter hændelsen) var evident hos 71,4 % af de Herceptin-behandlede patienter.
Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values ≥50 % after the event) was evident for 71.4 % of Herceptin-treated patients.
Reversible hæmolytiske reaktioner er blevet observeret hos patienter, især patienter med andre blodtyper end 0, der er i immunmodulerende behandling.
Reversible haemolytic reactions have been observed in patients, especially those withnon-0 blood groups in immunomodulatory treatment.
Reversible hæmolytiske reaktioner er observeret hos patienter, særligt dem med blodtype A, B og AB.
Reversible haemolytic reactions have been observed in patients, especially those with blood groups A, B, and AB.
Revertering af neutropeni:
For reversal of neutropenia:
Revestive 5 mg pulver til injektionsvæske, opløsning Teduglutid
Revestive 5 mg powder for solution for injection Teduglutide
Revestive anvendes til behandling af voksne og børn på 1 år og derover med korttarmssyndrom.
Revestive is used to treat adults and children from the age of 1 year with short bowel syndrome.
Revestive anvendes, efter at tarmen har "tilpasset sig" (dvs. tarmens funktion har ændret sig for at opveje den mindskede længde efter operationen).
Revestive is used after ‘intestinal adaptation’ has occurred (changes in the function of the bowel to compensate for its reduced size following surgery).
Revestive blev undersøgt i et 12-ugers åbent klinisk studie hos 42 pædiatriske personer i alderen 1 år til og med 14 år med SBS, der var afhængige af parenteral ernæring.
Revestive was studied in a 12-week, open-label, clinical study in 42 paediatric subjects aged 1 year through 14 years with SBS who were dependent on parenteral nutrition.
Revestive blev undersøgt i to hovedundersøgelser.
Revestive was studied in two main studies.
Revestive bør ikke gives, hvis der påvises kræft under koloskopien.
Revestive should not be used if a cancer is detected during your colonoscopy.
Revestive er et lægemiddel, der indeholder det aktive stof teduglutid.
Revestive is a medicine that contains the active substance teduglutide.
Revestive er ikke undersøgt hos patienter med svære, klinisk ustabile samtidige sygdomme (f.eks. kardiovaskulære, respiratoriske, renale, infektiøse, endokrine og hepatiske eller i centralnervesystemet) eller hos patienter med maligne lidelser inden for de sidste 5 år (se pkt.
Revestive has not been studied in patients with severe, clinically unstable concomitant diseases, (e.g., cardiovascular, respiratory, renal, infectious, endocrine, hepatic, or CNS), or in patients with malignancies within the last five years (see section 4.3).
Revestive er indiceret til behandling af patienter på 1 år og derover med korttarmssyndrom.
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome.
Revestive er pulver og solvens til injektionsvæske, opløsning (5 mg pulver i hætteglas, 0,5 ml solvens i en fyldt injektionssprøjte).
Revestive is a powder and solvent for solution for injection (5 mg powder in vial, 0.5 ml solvent in pre-filled syringe).
Revestive er til injektion under huden (subkutan injektion).
Revestive is for injection under the skin (subcutaneous injection).
Revestive må ikke anvendes hos patienter, der har kræft eller formodes at have kræft.
Revestive must not be used in patients who have, or are suspected to have, a cancer.
Revestives sikkerhed og virkning hos børn under 1 år er ikke klarlagt.
The safety and efficacy of Revestive in children below 1 year of age have not been established.
Revinty Ellipta 184 mikrogram/22 mikrogram inhalationspulver fluticasonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Revinty Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Revinty Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt.
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
revinty ellipta 184/22
revinty ellipta 184:22
Revinty Ellipta 184/22 mikrogram er ikke indiceret til KOL-patienter.
Revinty Ellipta 184/22 micrograms is not indicated for patients with COPD.
Revinty Ellipta 184/22 µg virkede imidlertid ikke bedre end Revinty Ellipta 92/22 µg.
However, there was no improvement of Revinty Ellipta 184/22 microgram over Revinty Ellipta 92/22 microgram.
Revinty Ellipta 92 mikrogram/22 mikrogram inhalationspulver fluticasonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Revinty Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt Revinty Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt.
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed
revinty ellipta 92/22
revinty ellipta 92:22
Revinty Ellipta 92/22 µg (mikrogram) (92 µg fluticasonfuroat og 22 µg vilanterol) kan anvendes til behandling af både astma og KOL, mens Revinty
Revinty Ellipta 92/22 microgram (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can be used for the
Revinty Ellipta anvendes desuden til lindring af symptomerne på kronisk obstruktiv lungesygdom (KOL) hos voksne, som tidligere har haft anfald med forværring af sygdommen trods regelmæssig behandling.
Revinty Ellipta is also used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Revinty Ellipta bør ikke anvendes i kombination med andre langtidsvirkende beta2-agonister eller lægemidler, der indeholder langtidsvirkende beta2-agonister.
Revinty Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long- acting beta2-adrenergic agonists.
Revinty Ellipta bør kun overvejes til gravide, hvis de forventede fordele opvejer risikoen.
Revinty Ellipta should only be considered for pregnant women if the expected benefits outweigh the risks.
Revinty Ellipta er et hvidt pulver.
Revinty Ellipta is a white powder.
Revinty Ellipta er et lægemiddel, der indeholder de aktive stoffer fluticasonfuroat og vilanterol.
Revinty Ellipta is a medicine that contains the active substances fluticasone furoate and vilanterol.
Revinty Ellipta er indiceret til behandling af astma hos voksne og unge på 12 år og derover, hvor behandling med et kombinationspræparat (langtidsvirkende beta2-agonist og inhalationssteroid) er hensigtsmæssig: hos patienter, der ikke er velkontrolleret på inhalationssteroid og korttidsvirkende beta2-agonist ved behov.
Revinty Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
Revinty Ellipta indeholder to aktive stoffer.
Revinty Ellipta contains two active substances.
Revinty Ellipta var genstand for tre hovedundersøgelser vedrørende astmabehandling med deltagelse af i alt over 3 200 patienter.
For the treatment of asthma, Revinty Ellipta was investigated in three main studies involving a total of over 3,200 patients.
Revinty Ellipta var i alle styrker mere effektivt til at mindske antallet af anfald med forværring af KOL end vilanterol alene.
Revinty Ellipta at all strengths was more effective in reducing the number of COPD flare-ups than vilanterol alone.
RevitaCAM 5 mg/ml mundhulespray, opløsning, til hunde
RevitaCAM 5mg/ml oromucosal spray for Dogs
RevitaCAM indeholder meloxicam, som tilhører gruppen af lægemidler kaldet non-steroide antiinflammatoriske lægemidler (NSAID'er).
RevitaCAM contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Revlimid 10 mg hårde kapsler
Revlimid 10 mg hard capsules
Revlimid 10 mg hårde kapsler er blågrønne/Lysegule og påtrykt “REV 10 mg”.
Revlimid 10 mg hard capsules are blue-green/pale yellow, with “REV 10 mg” written on them.
Revlimid 10 mg hårde kapsler lenalidomid
Revlimid 10 mg hard capsules lenalidomide
Revlimid 10 mg hårde kapsler:
Revlimid 10 mg hard capsules:
Revlimid 15 mg hårde kapsler
Revlimid 15 mg hard capsules
Revlimid 15 mg hårde kapsler er lyseblå/hvide og påtrykt ”REV 15 mg”.
Revlimid 15 mg hard capsules are pale blue/white, with “REV 15 mg” written on them.
Revlimid 15 mg hårde kapsler lenalidomid
Revlimid 15 mg hard capsules lenalidomide
Revlimid 15 mg hårde kapsler:
Revlimid 15 mg hard capsules:
Revlimid 2,5 mg hårde kapsler
Revlimid 2.5 mg hard capsules
Revlimid 2,5 mg hårde kapsler er blågrønne/hvide og påtrykt “REV 2.5 mg”.
Revlimid 2.5 mg hard capsules are blue-green/white, with “REV 2.5 mg” written on them.
Revlimid 2,5 mg hårde kapsler lenalidomid
Revlimid 2.5 mg hard capsules lenalidomide
Revlimid 2,5 mg hårde kapsler:
Revlimid 2.5 mg hard capsules:
Revlimid 20 mg hårde kapsler
Revlimid 20 mg hard capsules
Revlimid 20 mg hårde kapsler er blå-grønne/Lyseblå og påtrykt ”REV 20 mg”.
Revlimid 20 mg hard capsules are blue-green/pale blue, with “REV 20 mg” written on them.
Revlimid 20 mg hårde kapsler lenalidomid
Revlimid 20 mg hard capsules lenalidomide
Revlimid 20 mg hårde kapsler:
Revlimid 20 mg hard capsules:
Revlimid 25 mg hårde kapsler
Revlimid 25 mg hard capsules
Revlimid 25 mg hårde kapsler er hvide og påtrykt ”REV 25 mg”.
Revlimid 25 mg hard capsules arewhite, with “REV 25 mg” written on them.
Revlimid 25 mg hårde kapsler lenalidomid
Revlimid 25 mg hard capsules lenalidomide
Revlimid 25 mg hårde kapsler:
Revlimid 25 mg hard capsules:
Revlimid 5 mg hårde kapsler
Revlimid 5 mg hard capsules
Revlimid 5 mg hårde kapsler er hvide og påtrykt “REV 5 mg”.
Revlimid 5 mg hard capsules are white, with “REV 5 mg” written on them.
Revlimid 5 mg hårde kapsler lenalidomid
Revlimid 5 mg hard capsules lenalidomide
Revlimid 5 mg hårde kapsler:
Revlimid 5 mg hard capsules:
Revlimid 7,5 mg hårde kapsler
Revlimid 7.5 mg hard capsules
Revlimid 7,5 mg hårde kapsler er lysegule/hvide og påtrykt”REV 7.5 mg”.
Revlimid 7.5 mg hard capsules are pale yellow/white, with “REV 7.5 mg” written on them.
Revlimid 7,5 mg hårde kapsler lenalidomid
Revlimid 7.5 mg hard capsules lenalidomide
Revlimid 7,5 mg hårde kapsler:
Revlimid 7.5 mg hard capsules:
Revlimid anbefales ikke til børn og unge under 18 år.
Revlimid is not recommended for use in children and adolescents under 18 years.
Revlimid anvendes alene til at behandle voksne patienter, der tidligere er blevet behandlet for MCL.
Revlimid is used alone to treat adult patients who have been diagnosed with previously-treated MCL.
Revlimid anvendes hos patienter, der har en genetisk anomali (kaldet 5q-mangel) og lavere risiko for AML, og det anvendes, når andre behandlinger ikke er egnede.
Revlimid is used in patients who have a genetic abnormality (called deletion 5q) and are at a lower risk of AML, and it is used when other treatments are not adequate.
Revlimid anvendes hos voksne mod:
Revlimid is used in adults for:
Revlimid anvendes kun til nydiagnosticerede patienter, hvis det ikke er muligt at behandle dig med en knoglemarvstransplantation.
Revlimid is only used in newly diagnosed patients when you are unable to be treated with a bone marrow transplant.
Revlimid anvendes til behandling af multipelt myeloma, myelodysplastiske syndromer og mantelcellelymfom, som er sygdomme, der påvirker blodceller og knoglemarv.
Revlimid is used for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, which are conditions affecting blood cells and bone marrow.
Revlimid blev sammenlignet med et passende lægemiddel valgt af patientens læger, og behandlingens virkning blev hovedsagelig bedømt i forhold til, hvor lang tid, der gik, inden sygdommen blev værre.
Revlimid was compared with an appropriate medicine chosen by the patients’ doctors, and the main measure of effectiveness was how long it took until the disease got worse.
Revlimid bruges alene til at behandle voksne patienter, der er blevet diagnosticeret med myelodysplastisk syndrom, når følgende gælder:
Revlimid is used alone to treat adult patients who have been diagnosed with myelodysplastic syndromes, when all of the following apply:
Revlimid bør indtages på cirka samme tidspunkt på de planlagte dage.
Revlimid capsules should be taken at about the same time on the scheduled days.
Revlimid er et lægemiddel mod kræft, som indeholder det aktive stof lenalidomid.
Revlimid is a cancer medicine that contains the active substance lenalidomide.
Revlimid er indiceret til behandling af patienter med transfusionsafhængig anæmi, der skyldes lav- eller intermediær-1-risiko myelodysplastisk syndrom forbundet med en isoleret 5q-deletion (Del (5q)) cytogenetisk anomali, når andre behandlingsmuligheder er utilstrækkelige.
Revlimid is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Revlimid hos patienter med myelomatose, der tidligere har fået mindst én anden type behandling
Revlimid in patients with multiple myeloma who have had at least one other type of treatment before
Revlimid hos patienter med nydiagnosticeret myelomatose
Revlimid in patients newly diagnosed with multiple myeloma
Revlimid i kombination med dexamethason er indiceret til behandling af voksne patienter med myelomatose, som allerede har fået mindst én behandling.
Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Revlimid indeholder det aktive stof ’lenalidomid’.
Revlimid contains the active substance ‘lenalidomide’.
Revlimid indeholder lactose
Revlimid contains lactose
Revlimid indeholder lactose.
Revlimid contains lactose.
Revlimid kan forhindre, at tegn og symptomer fra myelomatose bliver værre.
Revlimid can stop the signs and symptoms of multiple myeloma getting worse.
Revlimid kan ligeledes forårsage blodpropper i årerne (trombose).
Revlimid may also cause blood clots in the veins (thrombosis).
Revlimid kan nedsætte antallet af de hvide blodlegemer, som bekæmper infektioner og også af de blodlegemer, som hjælper blodet med at størkne (blodplader), hvilket kan føre til blødningsforstyrrelser, f.eks. næseblod og blå mærker.
Revlimid may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders e.g. nosebleeds and bruising.
Revlimid kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Revlimid can cause side effects, although not everybody gets them.
Revlimid kan øge antallet af raske røde blodlegemer, som kroppen danner, ved at reducere antallet af unormale celler:
Revlimid can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:
Revlimid lenalidomid
Revlimid lenalidomide
Revlimid og de lægemidler, du tager i kombination med Revlimid, tages på visse dage i løbet af 4 uger (28 dage).
Revlimid and the medicines you take in combination with Revlimid are taken on certain days over 4 weeks (28 days).
Revlimid sammen med et antiinflammatorisk lægemiddel, der kaldes ’dexamethason’.
Revlimid together with an anti-inflammatory medicine called ‘dexamethasone’.
Revlimid sammen med kemoterapi, der kaldes ’melphalan’, og et immunundertrykkende lægemiddel, der kaldes ’prednison’.
Revlimid together with a chemotherapy medicine called ‘melphalan’ and an immunosuppressant medicine called ‘prednisone’.
Revlimid tages i behandlingscyklusser på hver 28 dage. (se ovenstående “Behandlingscyklus”).
Revlimid is taken in treatment cycles, each cycle lasting 28 days (see above “Treatment cycle”).
Revlimid tages i gentagne cyklusser på 28 dage: Patienten tager lægemidlet én gang dagligt i 21 dage, omkring samme tid hver dag, efterfulgt af en pause på syv dage.
Revlimid is taken in repeated 28-day cycles: the patient takes the medicine once a day for 21 days at around the same time each day, followed by seven days off the medicine.
Revlimid tages sammen med et antiinflammatorisk lægemiddel, der kaldes ’dexamethason’.
Revlimid is taken together with an anti-inflammatory medicine called ‘dexamethasone’.
Revlimid udskilles i sæd fra mennesker.
Revlimid passes into human semen.
Revlimid var genstand for to hovedundersøgelser, der omfattede 704 patienter, som tidligere var blevet behandlet for multipelt myeloma.
Revlimid has been studied in two main studies involving 704 patients with previously treated multiple myeloma.
Revlimid var mere effektivt end placebo til at forhindre forværring af tidligere behandlet multipelt myeloma.
Revlimid was more effective than placebo at preventing a worsening of previously treated multiple myeloma.
Revlimid virker ved at påvirke kroppens immunsystem og direkte angribe kræften.
Revlimid works by affecting the body’s immune system and directly attacking the cancer.
Revlimidkapsler indeholder lactose, og bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form for hereditær lactasemangel (Lapp Lactase deficiency) eller glucose/galactosemalabsorption.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Revnedannelse, dannelse af sårskorper, skorpedannelse, drænering, sivning Smerter, brænden, ømhed
Cracking, scabbing, crusting, draining, oozing Pain, burning, soreness
Revolade 12,5 mg filmovertrukne tabletter er runde, bikonvekse, hvide og præget ”GS MZ1” og ”12,5” på den ene side.
Revolade 12.5 mg film-coated tablets are round, biconvex, white, debossed with ‘GS MZ1’ and ‘12.5’ on one side.
Revolade 25 mg filmovertrukne tabletter er runde, bikonvekse, hvide og præget ”GS NX3” og ”25” på den ene side.
Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with ‘GS NX3’ and ‘25’ on one side.
Revolade 25 mg pulver til oral suspension
Revolade 25 mg powder for oral suspension:
Revolade 25 mg pulver til oral suspension (eltrombopag)
Revolade 25 mg powder for oral suspension (eltrombopag)
Revolade 25 mg pulver til oral suspension fås i sæt, der indeholder 30 breve; hvert brev indeholder et rødbrunt til gult pulver.
Revolade 25 mg powder for oral suspension is available in kits containing 30 sachets; each sachet contains a reddish-brown to yellow powder.
Revolade 50 mg filmovertrukne tabletter er runde, bikonvekse, brune og præget ”GS UFU” og ”50” på den ene side.
Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with ‘GS UFU’ and ‘50’ on one side.
Revolade 75 mg filmovertrukne tabletter er runde, bikonvekse, pink og præget ”GS FFS” og ”75” på den ene side.
Revolade 75 mg film-coated tablets are round, biconvex, pink, debossed with ‘GS FFS’ and ‘75’ on one side.
Revolade anvendes til behandling af:
Revolade is used for the treatment of:
Revolade anvendes til patienter på 1 år og derover, som ikke responderer på behandling med lægemidler som kortikosteroider eller immunoglobuliner. trombocytopeni hos patienter med kronisk (langvarig) hepatitis C, en leversygdom, der skyldes en infektion med hepatitis C-virus, når sværhedsgraden af trombocytopeni gør, at antiviral terapi ikke er mulig erhvervet svær aplastisk anæmi (en sygdom, hvor knoglemarven ikke producerer nok blodceller) hos voksne patienter.
Revolade is used in patients aged 1 year and above who do not respond to treatment with medicines such as corticosteroids or immunoglobulins; thrombocytopenia in adult patients with chronic (long-term) hepatitis C, a disease of the liver caused by infection with the hepatitis C virus, when the severity of thrombocytopenia is preventing antiviral therapy; acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells) in adult patients.